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1098-102 C-Reactive Protein on Admission Is an Independent 
Predictor of One-Year Mortality in Patients With Acute 
Myocardial Infarction: A Prospective Study
Mahmoud Suleiman, Riad Mahamid, Rania Khatib, Walter Markiewicz, Oren Zinder, 
Michael Kapeliovich, Yishai Levy, Haim Hammerman, Doron Aronson, Rambam Medical 
Center, Haifa, Israel
Background: Acute myocardial infarction (AMI) is associated with a marked increase in
C-reactive protein (CRP) - a marker of systemic inflammation. Inflammatory processes in
the infarcted myocardium are thought to contribute to infarct expansion and ventricular
remodeling. However, little data is available on the prognostic value of CRP in AMI.
Methods: CRP was measured within 12-24 hours of symptoms onset in a prospective
series of 448 patients (pts) with AMI (age 62 ± 13 y; 337 with ST-elevation AMI). The rela-
tion of CRP to 1-year mortality or heart failure was evaluated in pts who survived the
acute phase and discharged from hospital using Cox proportional-hazards model with
the following covariates: age, gender, diabetes, prior MI, Killip class, peak CK, systolic
blood pressure on admission, ST-elevation MI, anterior MI, reperfusion therapy, and ejec-
tion fraction.
Results: During hospital stay 52 pts died or developed HF. Of the remaining 396 patients,
43 (11%) of pts died (n = 25) or developed heart failure (n = 18) during 1 year. Kaplan-
Meier survival curves according to tertiles of CRP are shown in the Figure. In a Cox's
multivariate analysis, the adjusted relative risk of CRP in the upper tertile compared to
the lower tertile was 4.0 (95% CI 1.3-11.7, P = 0.01).
Conclusion: A single CRP measurement on admission is a strong predictor of 1-year
mortality or the development of heart failure after hospital discharge in pts with AMI inde-
pendent of infarct size and other traditional predictors of outcome.
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1099-85 Invasive Versus Conservative Treatment of Patients 
With Stable Angina and First Angiographic Diagnosis of 
Coronary Artery Disease in Germany: Results of the 
STAR Registry
Anselm K. Gitt, Rudolf Schiele, Harm Wienbergen, Christina Vogel, Tobias Heer, Martin 
G. Gottwik, Jochen Senges, The STAR Study Group, Herzzentrum Ludwigshafen, 
Ludwigshafen, Germany, Klinikum Nuernberg Sued, Nuernberg, Germany
Background: Coronary artery disease (CAD) contributes considerably to the overall
morbidity and mortality of cardiovascular disease in Germany. Little information exist on
the extent of CAD in patients (pts) with stable angina pectoris (AP) as well as their inva-
sive and medical treatment in clinical practice.
Methods: Between September 2001 and March 2003, consecutive pts with stable AP, in
whom CAD was documented angiographically for the first time, were enrolled into the
STAR-Registry (STable Angina Registry, 53 hospitals). We compared pts undergoing PCI
versus no PCI at the time of first invasive diagnosis of CAD.
Results: Out of 1964 consecutive pts with stable AP, 898 (46%) underwent PCI at the
time of first invasive diagnosis of CAD. 
Conclusion: Almost half of the pts with angiographically documented CAD and stable 
AP were treated by PTCA at the time of the invasive diagnosis, these pts were younger 
and more often had 1-vessel-disease. One-year mortality was lower in patients treated 
with PCI than in patients not treated with PCI at the time of CAD diagnosis (3.0% vs 
4.3%). Patients without PCI at the time of CAD-diagnosis more often had multi-vessel 
disease and underwent CABG during the one-year follow-up in 42.7%.
1099-86 The Medicine, Angioplasty, or Surgery Study (MASS II): 
Analyses in Male and Female Populations of Medical 
Therapy, Coronary Angioplasty, and Bypass Surgery 
Study During the First Year of Follow-Up
Paulo R. Soares, Whady A. Hueb, Bernard J. Gersh, Desiderio Favarato, Neusa H. 
Lopes, Luiz AM Cesar, Sergio A. Oliveira, Jose AF Ramires, Heart Institute University of 
Sao Paulo, Sao Paulo-SP, Brazil
There are differences in the outcome of patients submitted to angioplasty and surgery
according to gender, generally the prognosis is worse among female patients. In MASS II
study we compared medical treatment (MT), surgery (CABG) and angioplasty (PTCA) in
patients with multivessel coronary disease. The present study analyzed the 1 year fol-
low–up results in female and male populations. 611 patients were randomly assigned to
undergo CABG, (203) to PTCA (205) and (203) to MT. The primary end point was the
combined occurrence of death, myocardial infarction or new revascularization in the first
year of follow-up. The results are presented in the table: (MI= Myocardial infarction) (NR=
New revascularization) (CE= Combined events)
Conclusion: In MASS II during the first year follow-up study there were no statistical dif-
ferences in isolated and combined events between male and female patients in the three
therapeutic groups. In the 1 year follow-up the outcomes in the female population were
statistically similar in the three therapeutic strategies but in the male population we
observed a higher rate of MI and CE in the PTCA group and the lowest rate of NR was
observed in men treated initially with CABG.
PCI
for Stable Angina
n = 898
No PCI
for Stable Angina
n = 1066
p-value
Age [years] 5 8 <0.001
Male Gender 69 % 71 % ns
AP CCS II+ 88.2 % 79.4 % <0.001
Prior MI .9 % 0.4 % <0.001
Prior Stroke / TIA .3 % .0 % ns
1-Vessel-Disease 7.9 % 2.7 % <0.001
2-Vessel-Disease 30.2 % 29.5 % ns
3-Vessel-Disease 11.9 % 37.7 % <0.001
Chronic Medical Therapy
Aspirin 96.4 84.6 <0.001
Betablocker 78.7 75.6 ns
ACE-Inhibitors 59.5 60.1 ns
tatins 8.2 9.7 <0.001
-Year-Complications o:p> o:p>
eath .0 % .3 % 0.042
Non-fatal MI 3.0 % 1.7 % ns
Stroke 1.1 % 2.0 % ns
Re-PCI 6.1 % .6 % <0.001
CABG .4 % 2.7 % <0.001
Hospitalisation for UA 17.6 % 13.5 % 0.02
1
Male N Death Non-fatal MI NR CE
PTCA 136 3,7 9,6* 15,4# 28,7$
MT 140 2,1 3,6* 7,9# 13,6$
CABG 147 3,4 2,0* 0,7# 6,1$
Female N Death Non-fatal MI NR CE
PTCA 69 5,8 5,8 8,7 20,3
MT 63 0,0 1,6 7,9 9,5
CABG 56 5,4 1,8 0,0 7,1
* p = 0,01 # p < 0,0001 $ p < 0,0001
